Novo Nordisk A/S (NOVO-B.CO)
| Previous Close | 912.90 |
| Open | 911.00 |
| Bid | 901.90 x 0 |
| Ask | 903.30 x 0 |
| Day's Range | 901.10 - 919.00 |
| 52 Week Range | 504.40 - 932.00 |
| Volume | |
| Avg. Volume | 2,711,252 |
| Market Cap | 4.024T |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 45.39 |
| EPS (TTM) | 19.90 |
| Earnings Date | Aug 07, 2024 |
| Forward Dividend & Yield | 12.80 (1.40%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | 920.44 |
ZacksPharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
